Summary Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 188.8.131.52) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Heparanase - Drugs In Development, 2021, outlays comprehensive information on the Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 184.108.40.206) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 220.127.116.11) - Heparanase is an endoglycosidase which cleaves heparan sulfate (HS) and hence participates in degradation and remodeling of the extracellular matrix (ECM). Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells. The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also non-enzymatic activities, independent of its involvement in ECM degradation. Among these, are the enhancement of Akt signaling, stimulation of PI3K- and p38-dependent endothelial cell migration, and up regulation of VEGF, all contributing to its potent pro-angiogenic activity. Inhibiting the enzyme is beneficial in treatment of cancer.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Ophthalmology, Hematological Disorders and Immunology which include indications Coronavirus Disease 2019 (COVID-19), Pancreatic Cancer, Retinopathy, Blood Coagulation, Breast Cancer, Dengue Fever, Dry (Atrophic) Macular Degeneration, Head And Neck Cancer, Inflammation, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Refractory Multiple Myeloma, Solid Tumor, Triple-Negative Breast Cancer (TNBC) and Wet (Neovascular / Exudative) Macular Degeneration.
Furthermore, this report also reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 18.104.22.168) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 22.214.171.124) - The report reviews Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 126.96.36.199) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 188.8.131.52) targeted therapeutics and enlists all their major and minor projects - The report assesses Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 184.108.40.206) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 220.127.116.11) targeted therapeutics
Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 18.104.22.168)Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 22.214.171.124) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
Retinoic Acid Receptor Gamma - Drugs In Development, 2021 Summary Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the...
411 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Nov 2021
Toxicology is the study of adverse effects that occur in living organisms and its environment due to chemicals, physical or biological substances at ambient exposure levels. Toxicology testing regulations are already in place for most of the developed countries across industries such as chemicals, pesticides, consumer...
The global oxidative stress assay market reached a value of US$ 836 Million in 2020. Looking forward, the analyst expects the market to grow at a CAGR of 9.7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc., Quest Diagnostics, Thermo Fisher Scientific Inc., Pfizer, Bristol-Myers Squibb, Merck & Co. Inc., Tepnel Pharma Services, Abbott Laboratories, Takeda Pharmaceutical Company Ltd., and Eli Lilly and Company. The global precision medicine...
The analyst presents post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions. The report...
Cushing’s Syndrome - Opportunity Assessment and Forecast to 2030 Summary Cushing’s Syndrome is a disorder caused by the body’s exposure to an excess of the hormone cortisol.Cortisol affects all tissues and organs in the body, and collectively these effects are known as CS. This disorder can...
The aptamers market valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period. Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages...
The global chromatography resins market grew at a CAGR of around 7% during 2015-2020. Chromatography resins provide support to polysaccharide beads that are packed into a column. They are available with different purification efficiency, flow resistance and binding capacity. Some of the commonly utilized chromatography...
The global chemoinformatics market exhibited strong growth during 2015-2020. Looking forward, the analyst expects the market to grow at a CAGR of 13% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic...
143 pages •
By The Business Research Company
• Oct 2021
Organ-On-Chip (OOC) Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global OOC market as it emerges from the COVID 19 shut down. Description: Where is the largest and fastest...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.